Cargando…

Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era

In April 2014, the World Health Organization announced the beginning of a post-antibiotic era and declared antimicrobial resistance (AMR) a public health priority demanding global action. If no action is taken, by 2050 AMR will kill more people each year than cancer, with 10 million estimated annual...

Descripción completa

Detalles Bibliográficos
Autor principal: Totsika, Makrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112752/
http://dx.doi.org/10.2174/2210303106666160506120057
_version_ 1782468066954706944
author Totsika, Makrina
author_facet Totsika, Makrina
author_sort Totsika, Makrina
collection PubMed
description In April 2014, the World Health Organization announced the beginning of a post-antibiotic era and declared antimicrobial resistance (AMR) a public health priority demanding global action. If no action is taken, by 2050 AMR will kill more people each year than cancer, with 10 million estimated annual deaths at a cost of $100 trillion to the global economy. New therapies to tackle multidrug resistant bacterial pathogens are urgently needed. Unlike traditional antibiotics, antivirulence drugs inhibit bacterial virulence instead of growth promising to offer a new class of superior therapeutics that will be ‘evolution-proof’ and ‘tailored-spectrum’. This mini-review discusses the latest emerging evidence on the promised benefits of antivirulence drugs over conventional antibiotics, also highlighting the challenges in evaluating these properties for each of the diverse virulence targets that are currently under investigation. The author argues that overcoming such challenges early in the development process constitutes an important step towards successfully progressing each of the expanding number of antivirulence strategies into next-generation therapies for common human and animal infections that are becoming increasingly refractory to all available antibiotics.
format Online
Article
Text
id pubmed-5112752
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-51127522017-01-06 Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era Totsika, Makrina Curr Med Chem Article In April 2014, the World Health Organization announced the beginning of a post-antibiotic era and declared antimicrobial resistance (AMR) a public health priority demanding global action. If no action is taken, by 2050 AMR will kill more people each year than cancer, with 10 million estimated annual deaths at a cost of $100 trillion to the global economy. New therapies to tackle multidrug resistant bacterial pathogens are urgently needed. Unlike traditional antibiotics, antivirulence drugs inhibit bacterial virulence instead of growth promising to offer a new class of superior therapeutics that will be ‘evolution-proof’ and ‘tailored-spectrum’. This mini-review discusses the latest emerging evidence on the promised benefits of antivirulence drugs over conventional antibiotics, also highlighting the challenges in evaluating these properties for each of the diverse virulence targets that are currently under investigation. The author argues that overcoming such challenges early in the development process constitutes an important step towards successfully progressing each of the expanding number of antivirulence strategies into next-generation therapies for common human and animal infections that are becoming increasingly refractory to all available antibiotics. Bentham Science Publishers 2016-02 2016-02 /pmc/articles/PMC5112752/ http://dx.doi.org/10.2174/2210303106666160506120057 Text en © 2016 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/legalcode ), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Totsika, Makrina
Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
title Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
title_full Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
title_fullStr Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
title_full_unstemmed Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
title_short Benefits and Challenges of Antivirulence Antimicrobials at the Dawn of the Post-Antibiotic Era
title_sort benefits and challenges of antivirulence antimicrobials at the dawn of the post-antibiotic era
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112752/
http://dx.doi.org/10.2174/2210303106666160506120057
work_keys_str_mv AT totsikamakrina benefitsandchallengesofantivirulenceantimicrobialsatthedawnofthepostantibioticera